Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis
- PMID: 26131438
- PMCID: PMC4481026
- DOI: 10.4174/astr.2015.89.1.1
Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis
Abstract
The shaping of new blood vessels is a significant event in cancer growth and metastasis. Therefore, the molecular system of cancer angiogenesis has garnered considerable interest in cancer research. The vascular endothelial growth factor (VEGF) and VEGF receptor pathway are recognized as the key regulators of the angiogenic process. Activation of the VEGF/VEGF-receptor pathway initiates signaling cascades that promote endothelial cell growth, migration, and differentiation. Recently, VEGF was shown to play a role in the recruitment of bone marrow-derived endothelial progenitor cells to neovascularization sites. The role of VEGF in promoting tumor angiogenesis and the occurrence of human cancers has led to the rational design and development of agents that selectively target this pathway. Moreover, these anti-VEGF/VEGF receptor agents show therapeutic potential by inhibition of angiogenesis and tumor growth in preclinical models. In this review, we summarize the role of the VEGF pathway during tumor angiogenesis.
Keywords: Angiogenesis inhibitors; Cell hypoxia; Tumor microenvironment; Vascular endothelial growth factor receptors.
Conflict of interest statement
Figures


Similar articles
-
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.J Clin Oncol. 2005 Feb 10;23(5):1011-27. doi: 10.1200/JCO.2005.06.081. Epub 2004 Dec 7. J Clin Oncol. 2005. PMID: 15585754 Review.
-
Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.Curr Med Chem Anticancer Agents. 2003 Mar;3(2):95-117. doi: 10.2174/1568011033353452. Curr Med Chem Anticancer Agents. 2003. PMID: 12678905 Review.
-
Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.Recent Pat Anticancer Drug Discov. 2007 Jan;2(1):59-71. doi: 10.2174/157489207779561426. Recent Pat Anticancer Drug Discov. 2007. PMID: 18221053 Review.
-
Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.Oncologist. 2015 Jun;20(6):660-73. doi: 10.1634/theoncologist.2014-0465. Epub 2015 May 22. Oncologist. 2015. PMID: 26001391 Free PMC article. Review.
-
Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.Prog Biophys Mol Biol. 2013 Nov;113(2):333-54. doi: 10.1016/j.pbiomolbio.2013.10.001. Epub 2013 Oct 15. Prog Biophys Mol Biol. 2013. PMID: 24139944 Review.
Cited by
-
Expression of vascular endothelial growth factor (VEGF) in equine sarcoid.BMC Vet Res. 2018 Sep 3;14(1):266. doi: 10.1186/s12917-018-1576-z. BMC Vet Res. 2018. PMID: 30176852 Free PMC article.
-
The Prognostic Value of the Combination of Low VEGFR-1 and High VEGFR-2 Expression in Endothelial Cells of Colorectal Cancer.Int J Mol Sci. 2018 Nov 9;19(11):3536. doi: 10.3390/ijms19113536. Int J Mol Sci. 2018. PMID: 30423986 Free PMC article.
-
Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging.Cancers (Basel). 2024 Mar 30;16(7):1364. doi: 10.3390/cancers16071364. Cancers (Basel). 2024. PMID: 38611042 Free PMC article. Review.
-
Vascular Complications of Cancer Chemotherapy.Can J Cardiol. 2016 Jul;32(7):852-62. doi: 10.1016/j.cjca.2015.12.023. Epub 2015 Dec 28. Can J Cardiol. 2016. PMID: 26968393 Free PMC article. Review.
-
The tumor suppressor DACT3 sensitizes triple-negative breast cancer to apatinib by inhibiting the Wnt/β-catenin pathway.Transl Oncol. 2025 Aug 28;61:102509. doi: 10.1016/j.tranon.2025.102509. Online ahead of print. Transl Oncol. 2025. PMID: 40882561 Free PMC article.
References
-
- Folkman J, Kalluri R. Cancer without disease. Nature. 2004;427:787. - PubMed
-
- Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002;2:727–739. - PubMed
-
- Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004;4:839–849. - PubMed
-
- Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006;10:99–111. - PubMed
-
- Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–676. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources